Quest Diagnostics Inc (NYSE:DGX) reported strong financial results for the first quarter of 2026, with revenue reaching $2.9 billion, a 9.2% increase from the previous year. The company's organic revenue growth was 9%, and diagnostic information services revenue grew by 9.4%. Adjusted earnings per share (EPS) rose to $2.50, reflecting a 13% increase year-over-year, supported by productivity gains from automation and artificial intelligence. Quest raised its full-year revenue guidance to between $11.78 billion and $11.9 billion, indicating confidence in its ongoing strategic focus and momentum. However, the company faced challenges, including a 1.3% decline in revenue per requisition due to its collaborations with Fresenius Medical Care and Corewell Health. Additionally, cash from operations decreased to $278 million, down from $314 million the previous year, influenced by timing issues and higher bonus payments. Looking ahead, Quest anticipates potential negative impacts from weather and increased expenses related to Project Nova and fuel costs.